User login
Key clinical point: Initiation of 300 units/mL insulin glargine (Gla-300) or 100 units/mL degludec (Deg-100) was associated with similar improvements in glycemic control, no weight gain, and low rates of hypoglycemia in insulin-naive patients with type 2 diabetes (T2D).
Major finding: After 6 months, both Gla-300 and Deg-100 led to a significant and similar reduction in glycated hemoglobin (between group difference [Δ] −0.01%; P = .49) and fasting blood glucose (Δ −2.09 mg/dL; P = .74) levels, with no significant changes in body weight in both treatment groups. Overall, the incidence of hypoglycemia was low, with no severe episodes reported.
Study details: This was a retrospective study including insulin-naive patients with T2D who initiated Gla-300 and were propensity matched with those who initiated Deg-100 (n = 357).
Disclosures: This study was funded by Sanofi S.r.l., Milan, Italy. Some authors declared receiving lecture fees, consulting fees, research funding, or speaking honoraria from various sources, including Sanofi. M Larosa declared being an employee and holding stock in Sanofi.
Source: Fadini GP et al. Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY). Acta Diabetol. 2022 (Jul 21). Doi: 10.1007/s00592-022-01925-9
Key clinical point: Initiation of 300 units/mL insulin glargine (Gla-300) or 100 units/mL degludec (Deg-100) was associated with similar improvements in glycemic control, no weight gain, and low rates of hypoglycemia in insulin-naive patients with type 2 diabetes (T2D).
Major finding: After 6 months, both Gla-300 and Deg-100 led to a significant and similar reduction in glycated hemoglobin (between group difference [Δ] −0.01%; P = .49) and fasting blood glucose (Δ −2.09 mg/dL; P = .74) levels, with no significant changes in body weight in both treatment groups. Overall, the incidence of hypoglycemia was low, with no severe episodes reported.
Study details: This was a retrospective study including insulin-naive patients with T2D who initiated Gla-300 and were propensity matched with those who initiated Deg-100 (n = 357).
Disclosures: This study was funded by Sanofi S.r.l., Milan, Italy. Some authors declared receiving lecture fees, consulting fees, research funding, or speaking honoraria from various sources, including Sanofi. M Larosa declared being an employee and holding stock in Sanofi.
Source: Fadini GP et al. Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY). Acta Diabetol. 2022 (Jul 21). Doi: 10.1007/s00592-022-01925-9
Key clinical point: Initiation of 300 units/mL insulin glargine (Gla-300) or 100 units/mL degludec (Deg-100) was associated with similar improvements in glycemic control, no weight gain, and low rates of hypoglycemia in insulin-naive patients with type 2 diabetes (T2D).
Major finding: After 6 months, both Gla-300 and Deg-100 led to a significant and similar reduction in glycated hemoglobin (between group difference [Δ] −0.01%; P = .49) and fasting blood glucose (Δ −2.09 mg/dL; P = .74) levels, with no significant changes in body weight in both treatment groups. Overall, the incidence of hypoglycemia was low, with no severe episodes reported.
Study details: This was a retrospective study including insulin-naive patients with T2D who initiated Gla-300 and were propensity matched with those who initiated Deg-100 (n = 357).
Disclosures: This study was funded by Sanofi S.r.l., Milan, Italy. Some authors declared receiving lecture fees, consulting fees, research funding, or speaking honoraria from various sources, including Sanofi. M Larosa declared being an employee and holding stock in Sanofi.
Source: Fadini GP et al. Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY). Acta Diabetol. 2022 (Jul 21). Doi: 10.1007/s00592-022-01925-9